Alkermes (ALKS) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alkermes (ALKS) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 57.1% versus a loss of 30.8%. Over five years, MDGL leads with a +362.0% price change compared with +100.0% for ALKS. Madrigal Pharmaceuticals is the larger company by market cap ($8.81 billion vs $7.55 billion), about 1.2 times the size.
On valuation, Alkermes trades at a lower forward P/E (33.2x vs 36.5x for Madrigal Pharmaceuticals). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | MDGL |
|---|---|---|
| Share price | $44.94 | $379.10 |
| Market cap | $7.55B | $8.81B |
| 1-day change | -2.69% | -4.45% |
| YTD return | +60.61% | -34.90% |
| 1-year return | +57.08% | -30.82% |
| 5-year return | +100.00% | +361.98% |
| Forward P/E | 33.21 | 36.52 |
| EPS (TTM) | $-0.01 | $-5.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $958.40M |
| Revenue growth (YoY) | -5.25% | +432.05% |
| Net income (latest FY) | $241.66M | $-288.28M |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | -31.31% |
| Net margin | 16.37% | -30.08% |
| 52-week high | $55.67 | $615.00 |
| 52-week low | $27.00 | $353.54 |
| Distance from 52-week high | -19.27% | -38.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +28.48% | +81.69% |
| Average volume | 1.90M | 370.07K |
| Shares outstanding | 168.04M | 23.23M |
| Employees | 2,050 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALKS has outperformed MDGL by 87.9 percentage points over the past year.
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
ALKS vs MDGL FAQ
Which is bigger, Alkermes or Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $8.81B compared with $7.55B for Alkermes (ALKS).
Which stock has performed better over the past year, ALKS or MDGL?
ALKS returned +57.08% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.